Event reported in a literature article: journal of pediatric hematology/oncology 2014;00:000-000.Accepted for publication 10/03/2014."safety and outcomes of extracorporeal photopheresis with the therakos cellex system for graft-versus-host-disease in pediatric patients." (b)(6) year old boy, one of four patients (all four with liver involvement) in a retrospective review of twelve pediatric patients that failed to respond to the treatment died of multi-organ failure, no steroid tapering.Hsct indication: mds, myelodysplastic syndrome.Donor: (b)(6), matched unrelated donor (b)(6).Stem cell: pbsc (peripheral blood stem cell).Onset of gvhd (wk): 1.Gvhd treatment (pre-ecp): csa (cyclosporine), tacr (tacrolimus), mmf (mycophenolate mofetil), mp (methylprednisolone), atg (antithymocyte globulin).Internal between onset of gvhd and ecp (wk): 2.Gvhd type: acute (biopsy proven).Affected organs (stage in agvhd, score in cgvhd): skin (4), gis gastrointestinal (3), liver (2).Degree of gvhd: grade 4 acute gvhd.Improvement: acute grade 4 to 3.Ecp procedures: 8.Gvhd treatment during ecp: tacr, mmf, mp.Beginning of improvement (if any), (number of procedures): 4.Survival: expired.Current status: died of multi-organ failure, no steroid tapering.Date of death was not reported.
|
No lot number was reported, therefore, no batch record review was performed.There were no trends detected for complaint categories, death or multi-organ failure.(b)(6) year old male with grade 4 acute gvhd of mds died of multi-organ failure.Pt only had 8 ecp treatments.This case is serious and not related to ecp therapy.Therakos is reporting this out of an abundance of caution.Kit unique identifier (udi) #:.
|